We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

49 hedge funds and large institutions have $579M invested in VYNE Therapeutics in 2018 Q1 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0.98% more ownership

Funds ownership: 0% → 0.98% (+0.98%)

Holders
49
Holders Change
+49
Holders Change %
–
% of All Funds
1.12%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
49
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$136M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$69.1M
3
PA
Perceptive Advisors
New York
+$54M
4
VP
venBio Partners
California
+$49.4M
5
NHAS
Novo Holdings A/S
Denmark
+$46M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$682K +$613K +252 New
Morgan Stanley
27
Morgan Stanley
New York
$540K +$484K +199 New
Citadel Advisors
28
Citadel Advisors
Florida
$535K +$482K +198 New
LCM
29
Laurion Capital Management
New York
$481K +$433K +178 New
TA
30
Teachers Advisors
New York
$469K +$421K +173 New
TCIM
31
TIAA CREF Investment Management
New York
$448K +$401K +165 New
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$368K +$331K +136 New
Deutsche Bank
33
Deutsche Bank
Germany
$310K +$280K +115 New
GPCM
34
Granite Point Capital Management
Massachusetts
$304K +$275K +113 New
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$192K +$173K +71 New
AIG
36
American International Group
New York
$154K +$139K +57 New
New York State Common Retirement Fund
37
New York State Common Retirement Fund
New York
$132K +$119K +49 New
SO
38
STRS Ohio
Ohio
$67K +$60.8K +25 New
Barclays
39
Barclays
United Kingdom
$50K +$43.8K +18 New
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$43.3K +$38.9K +16 New
Legal & General Group
41
Legal & General Group
United Kingdom
$43K +$38.9K +16 New
Wells Fargo
42
Wells Fargo
California
$38K +$34.1K +14 New
Citigroup
43
Citigroup
New York
$32K +$29.2K +12 New
AIP
44
Ameritas Investment Partners
Nebraska
$20K +$19.5K +8 New
Bank of America
45
Bank of America
North Carolina
$18K +$17K +7 New
UBS Group
46
UBS Group
Switzerland
$14K +$12.2K +5 New
CCA
47
Catalyst Capital Advisors
New York
$9K +$7.3K +3 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$7K +$7.3K +3 New
PNC Financial Services Group
49
PNC Financial Services Group
Pennsylvania
$2K +$2.43K +1 New
1
2

VYNE Hedge Fund Activity: Q1 2018 in Review

49 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2018, worth a combined $579M.

Buyers outnumbered sellers: 49 funds opened new VYNE positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vivo Capital, opening a new position worth an estimated $136M.

  • 49 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2018, up from 0 in Q4 2017.
  • Funds reported $579M of VYNE Therapeutics stock for Q1 2018.
  • 49 funds opened new VYNE Therapeutics positions in Q1 2018 and 0 closed out, a net change of +49 holders.
  • The largest VYNE Therapeutics buyer in Q1 2018 was Vivo Capital, an estimated $136M added.

Based on aggregated 13F filings for Q1 2018.